Adjuvant anthracycline-taxane (AT) combinations for human epidermal growth factor receptor-2 (HER2) negative breast cancer have been widely studied and adopted due to improved survival outcomes in comparison to historical anthracycline-only regimens [1,2,3,4]. This evidence concerns the gene ERBB2 and breast cancer.